Gojji Announces Partnership with PerformRx to Provide Chronic Disease Management Products and Services

The Partnership will Allow Gojji to Provide Turnkey Services Through Its Integration with PerformRx’s Innovative Product and Service Offerings

Gojji, a data-driven chronic care management company, announced they have partnered with PerformRx, a URAC and NCQA-accredited full-service pharmacy benefit manager (PBM), to provide state-of-the-art chronic disease management products and best in class clinical services for their clients. This partnership will allow Gojji to provide turnkey services through its integration with PerformRx’s innovative product and service offerings.

Gojji shares the same vision and mission as PerformRx in using innovation to improve member outcomes and lower overall medical costs. Gojji’s comprehensive services provide continuous monitoring and intervention, which help bridge the gaps created by the enormous financial burden of chronic diseases where inappropriate medication use is very common. Their remote monitoring capability adds to the strength in delivering chronic disease management and medication optimization, and this has proven valuable, especially in times like today’s COVID-19 pandemic.

“We are very excited to join forces with PerformRx and offer our clinical services to their clients,” said Chris Chan, PharmD, Co-Founder and Chief Clinical Officer of Gojji. “Our clinical services have proven to save cost for our clients while improving outcomes for our patients. We are able to do this by combining technology and the expertise of our pharmacists and dietitians in a cost-effective manner. Our ultimate goal is to provide exceptional clinical service values to our health plan partners and our optional value-based payment model shows how confident we are in our product.”

SourceGojji

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version